Sorrento Therapeutics Stock Has Fallen 6% In A Week: Are Gains Now Expected?

Sorrento Therapeutics stock, a clinical stage biopharma company that develops treatments for cancer and neurodegenerative diseases among others, has fallen by 6% in the last week. But will the company’s stock resume its downward trajectory over the coming weeks, or is a rise in the stock imminent?..